Donepezil TDS

DRUG5 trials

Sponsors

Corium, Inc.

Conditions

Alzheimer's DiseaseHealthy SubjectsSensitizationSkin Irritation

Phase 1

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

CompletedNCT03259958

Corium, Inc.Alzheimer's Disease

Start: 2017-10-30End: 2018-03-14Updated: 2018-08-01

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

CompletedNCT03397862

Corium, Inc.Sensitization, Skin Irritation

Start: 2017-11-14End: 2018-04-02Updated: 2018-09-14

A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations

CompletedNCT03432195

Corium, Inc.Alzheimer's Disease

Start: 2018-01-31End: 2018-06-28Updated: 2018-08-07

A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)

CompletedNCT03438604

Corium, Inc.Alzheimer's Disease

Start: 2018-02-13End: 2018-06-30Updated: 2018-09-14

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

CompletedNCT04617782

Corium, Inc.Healthy Subjects

Start: 2020-12-08End: 2021-04-05Updated: 2024-09-19

Related Papers

A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Donepezil Transdermal Delivery System (P8-6.009)

Neurology2023-04-25

Bioequivalence and safety comparison of once‐weekly donepezil transdermal system with oral donepezil: results of a phase 1 pharmacokinetic study in healthy volunteers

Alzheimer s & Dementia2022-12-01

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Journal of Alzheimer s Disease2022-09-1616 citations